Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11271596 | 0.95 | CYP19A1 (0.46) | CYP19A1HTTKDM4EPOLBKMT2A | |
| SCHEMBL11182570 | 0.92 | POLB (0.43) | CYP19A1HTTKDM4EPOLBKMT2A | |
| SCHEMBL11261149 | 0.84 | CYP19A1 (0.43) | CYP19A1LMNA | |
| SCHEMBL11273790 | 0.84 | CYP19A1 (0.59) | CYP19A1HTTKDM4EPOLBKMT2A | |
| SCHEMBL11188697 | 0.84 | HMOX1 (0.51) | CYP19A1POLBKMT2ALMNAMEN1 | |
| SCHEMBL11270600 | 0.84 | NPSR1 (0.49) | CYP19A1POLBKMT2ALMNAMEN1 | |
| SCHEMBL5544140 | 0.83 | TSHR (0.58) | CYP19A1HTTPOLBKMT2ALMNA | |
| SCHEMBL7783933 | 0.83 | TSHR (0.58) | CYP19A1HTTPOLBKMT2ALMNA | |
| SCHEMBL10970720 | 0.83 | CYP19A1 (0.53) | CYP19A1HTTKDM4EPOLBKMT2A | |
| SCHEMBL10958885 | 0.83 | MEN1 (0.47) | CYP19A1HTTPOLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012360-B2 | Synergistic combinations of active ingredients | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-21 | — | — | US | disclosed |
| US-20130274101-A1 | Synergistic Fungicidal Active Substance Combinations | WACHENDORFF-NEUMANN ULRIKE (DE) | 2013-10-17 | — | — | US | disclosed |
| US-8324130-B2 | Synergistic active ingredient combinations | BAYER CROPSCIENCE AG (DE) | 2012-12-04 | — | — | US | disclosed |
| US-20120035050-A1 | Synergistic Combinations Of Active Ingredients | BAYER CROPSCIENCE AG (DE) | 2012-02-09 | — | — | US | disclosed |
| US-20090280981-A1 | SYNERGISTIC ACTIVE INGREDIENT COMBINATIONS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-11-12 | — | — | US | disclosed |
| US-5141553-A | ETHER DERIVATIVES OF SUBSTITUTED 1-HYDROXYALKYL-AZOLES AS FUNGICIDES AND PLANT GROWTH REGULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-25 | — | — | US | disclosed |
| US-4868196-A | Ether derivatives of substituted 1-hydroxyalkyl- azoles as fungicides and plant growth regulators | BAYER AKTIENGESELLSCHAFT (DE) | 1989-09-19 | — | — | US | disclosed |
| US-4742071-A | Novel 2-aryl-2-azolylmethyl-1,3-dioxepine fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 1988-05-03 | — | — | US | disclosed |
| EP-0224723-A1 | Process for the preparation of beta-hydroxyethyl-azole derivatives | BAYER AG (DE) | 1987-06-10 | — | — | EP | disclosed |
| EP-0080071-B1 | 2-IMIDAZOLYLMETHYL-2-PHENYL-1,3-DIOXOLANES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS FUNGICIDES | BAYER AG (DE) | 1987-05-13 | — | — | EP | disclosed |
| EP-0040744-B1 | AMINOPROPIOPHENONE OXIMES, PROCESSES FOR PREPARING THEM AND THEIR USE AS FUNGICIDES | BAYER AG (DE) | 1984-02-08 | — | — | EP | disclosed |
| EP-0085333-A2 | Ether derivatives from substituted 1-hydroxyalkyl azoles, process for their preparation as well as their use as fungicides and plant-growth regulators | BAYER AG (DE) | 1983-08-10 | — | — | EP | disclosed |
| US-4394380-A | HERBICIDES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-07-19 | — | — | US | disclosed |
| EP-0080071-A2 | 2-Imidazolylmethyl-2-phenyl-1,3-dioxolanes, process for their preparation and their use as fungicides | BAYER AG (DE) | 1983-06-01 | — | — | EP | disclosed |
| EP-0068144-A1 | 1,1-Diphenyl-2-triazolyl-ethanes, their preparation and their application as fungicides | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-01-05 | — | — | EP | disclosed |
| US-4349556-A | Pesticidally active 1-acyloxy-1-phenyl-2-azolyl-ethanes | BAYER AKTIENGESELLSCHAFT (DE) | 1982-09-14 | — | — | US | disclosed |
| US-4315016-A | FUNGICIDES | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-02-09 | — | — | US | disclosed |
| EP-0040744-A1 | Aminopropiophenone oximes, processes for preparing them and their use as fungicides | BAYER AG (DE) | 1981-12-02 | — | — | EP | disclosed |
| EP-0040740-A2 | Aminopropanol derivatives, process for their preparation and their use as fungicides | BAYER AG (DE) | 1981-12-02 | — | — | EP | disclosed |
| US-4102891-A | FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035050-A1 | Synergistic Combinations Of Active Ingredients | C1S, MAN2B1, MANBA | CYP19A1 725/4885HTT 3838/4885KDM4E 4311/4885 |
| US-20130274101-A1 | Synergistic Fungicidal Active Substance Combinations | GLRA1, GRM1, CYP1A2 | CYP19A1 51/4885HTT 4294/4885KDM4E 3437/4885 |
| US-20090280981-A1 | SYNERGISTIC ACTIVE INGREDIENT COMBINATIONS | CYP51A1, ERG28, CYP4X1 | CYP19A1 18/4885HTT 4568/4885KDM4E 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.